Genprex Inc (GNPX) has released an update.
Genprex has initiated the Phase 2a expansion of its Acclaim-1 clinical trial for Reqorsa® Therapy, with the first patient dosed in January 2024. This trial targets late-stage Non-Small Cell Lung Cancer patients with specific mutations, combining REQORSA with AstraZeneca’s Tagrisso®. Early results from Phase 1 showed promising tolerability and efficacy, with some patients showing extended progression-free survival. The company aims to complete Phase 2a enrollment by end of 2024 and anticipates interim analysis in 2025, while also cautioning that these forward-looking statements are subject to risks and uncertainties.
For further insights into GNPX stock, check out TipRanks’ Stock Analysis page.
For a comprehensive understanding of the announcement, you can read the full document here.
